Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin (2019 - 2025)

Biodesix (BDSX) has disclosed EBITDA Margin for 7 consecutive years, with 6.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 2571.0% year-over-year to 6.84%, compared with a TTM value of 31.5% through Dec 2025, up 1687.0%, and an annual FY2025 reading of 31.5%, up 1687.0% over the prior year.
  • EBITDA Margin was 6.84% for Q4 2025 at Biodesix, up from 32.39% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6.84% in Q4 2025 and bottomed at 220.85% in Q1 2022.
  • Average EBITDA Margin over 5 years is 87.47%, with a median of 63.77% recorded in 2023.
  • The sharpest move saw EBITDA Margin surged 14593bps in 2021, then crashed -20150bps in 2022.
  • Year by year, EBITDA Margin stood at 161.67% in 2021, then rose by 11bps to 144.58% in 2022, then soared by 68bps to 46.84% in 2023, then surged by 31bps to 32.55% in 2024, then skyrocketed by 79bps to 6.84% in 2025.
  • Business Quant data shows EBITDA Margin for BDSX at 6.84% in Q4 2025, 32.39% in Q3 2025, and 48.55% in Q2 2025.